 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Breakthrough Therapy Aiming To Solve The World's Mental Health Crisis The Breakthrough Therapy Aiming To Solve The World's Mental Health Crisis PR Newswire LONDON, Sept. 19, 2023 FN Media Group...

The Breakthrough Therapy Aiming To Solve The World's Mental Health Crisis

Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031 PR Newswire...

Global Psychedelic Therapeutics Market Size Expected To Reach $13.29 Billion By The Year 2031

Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates PR Newswire PALM BEACH, FL, Nov. 14, 2022 PALM BEACH, FL, Nov. 14, 2022...

Greater Prevalence of Anxiety & Depressive Disorders Driving Demand for New Anti-Anxiety Drug Candidates

Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics PR Newswire NEW YORK, Sept. 22, 2022 FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, Sept. 22, 2022 /PRNewswire/ -- Atlanta just became the...

Atlanta Becomes Latest City to Consider Decriminalizing Psychedelics

Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression PR Newswire NEW YORK, Aug. 10, 2022 FN Media Group Presents Microsmallcap.com Market...

Toronto Addiction Center Gets First-Ever Federal Grant to Study Effects of Magic Mushroom on Depression

Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders PR Newswire PALM BEACH, Fla., July 27, 2022 FinancialNewsMedia.comNews Commentary PALM BEACH, Fla., July 27, 2022 /PRNewswire...

Ketamine Ushering in New Era in the Pharmacology Therapies for Neurological Disorders

World's Richest Man Says Psychedelics Could Make a Real Difference in Mental Health World's Richest Man Says Psychedelics Could Make a Real Difference in Mental Health PR Newswire NEW YORK, June 15, 2022 FN Media Group Presents Microsmallcap.com Market Commentary NEW YORK, June 15, 2022...

World's Richest Man Says Psychedelics Could Make a Real Difference in Mental Health

---
- Why Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence
  for Digital Mental Therapies Why Some Psychedelic Assisted Therapy Clinics Are Turning
  To Artificial Intelligence for Digital Mental Therapies FinancialNewsMedia.com News
  Commentary PR Newswire PALM BEACH, Fla...


Why Some Psychedelic Assisted Therapy Clinics Are Turning To Artificial Intelligence for Digital Mental Therapies

---
- Cybin Inc. (NYSE:CYBN) (NEO:CYBN) (Cybin or the Company), a biotechnology company
  focused on progressing psychedelic therapeutics, today announced that Doug Drysdale,
  Chief Executive Officer, will be presenting virtually at Canaccord Genuitys 41st
  Annual Growth Conference on August 10, 2021. The...


Cybin to Present at Canaccord Genuitys 41st Annual Growth Conference on August 10th

Cybin, Inc. is a clinical-stage biopharmaceutical company. The company's mission is to create safe and effective psychedelic-based therapeutics to address the large unmet need for new and innovative treatment options for people who suffer from mental health conditions. Its goal of revolutionizing mental healthcare is supported by a network of world-class partners and internationally recognized scientists aimed at progressing proprietary drug discovery platforms, innovative drug delivery systems, and novel formulation approaches and treatment regimens. The company is currently developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, and has a research pipeline of investigational psychedelic-based compounds. The company was founded by Paul Glavine, Eric So, and John Kanakis on October 13, 2016 and is headquartered in Toronto, Canada.

Watchers	5,340
52-Wk Low	$0.21
52-Wk High	$0.715

Market Cap	$127.53M
Volume (M)	4.01M
52-Wk High	$0.715
52-Wk Low	$0.21

CYBN Cybin Inc

About

Feed

News

Fundamentals